Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Sumitomo Pharma Oncology, Inc. has presented updated preliminary data from a Phase 1/2 clinical study evaluating TP-3654 at the European Hematology Association 2023 Hybrid Congress. The investigational selective oral PIM1 kinase inhibitor is being tested in patients with myelofibrosis who were previously treated with or ineligible for JAK inhibitor therapy. Preliminary data showed spleen volume ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Sumitomo Pharma Oncology, Inc. has presented updated preliminary data from its ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy. The initial preliminary data was presented at the American Society of Hematology (ASH) Annual Meeting & Exposition 20..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms